Targeting EphA2: An Emerging Focus in Combating Tumor Drug Resistance and MetastasisTumor drug resistance and metastasis are major causes of cancer treatment failure and patient mortality. Confronting this clinical challenge, scientists have turned their attention to a critical "signaling hub" on cancer...
Detailed information

In-depth Dialogue on the "Core Triangle" of Inflammation: How IL-6, IL-1β, and TNF-α Interact to Drive Disease Progression?Inflammation is a key defense mechanism for maintaining homeostasis and responding to injury, but its dysregulation becomes a critical pathological basis for various chronic diseases. Interleukin-6 (IL-6), Interleukin-1β ...
Detailed information

Targeting TNFRSF13B: Dual-Target Strategies Usher in New Focus for Treating Tumors and Autoimmune DiseasesTNFRSF13B (TACI), a molecule playing a central role in immune regulation, has become a new focal point for cross-domain breakthroughs in tackling tumors and autoimmune diseases due to its functional diversity. Current re...
Detailed information

SIGLEC15: An Emerging Immune Checkpoint Target in Tumor ImmunotherapySIGLEC15 is an emerging immune checkpoint molecule widely expressed in various tumors, closely associated with immune evasion, treatment resistance, and poor prognosis. It plays a key role in tumor immunosuppression by i...
Detailed information

Metabolic Hub, Reprogramming Disease: SLC3A2 – From Amino Acid Transport Mechanism to Emerging Therapeutic TargetSLC3A2 (CD98hc) is far more than a typical transporter protein; it serves as a pivotal hub linking amino acid metabolism to cellular signaling. It plays a critical role in cancer, neurological, metabolic, and immune dise...
Detailed information

The "Achilles' Heel" of Cancer Stem Cells: LGR5 Becomes Focus of $8 Billion AcquisitionOn September 29, Genmab announced it had entered into an acquisition agreement with Merus to purchase all outstanding shares of the latter for $97 per share, totaling approximately $8 billion. The LGR5/EGFR bispecific an...
Detailed information

CD45: The Immune Cell "Gatekeeper" Protein – Why is it Emerging as a Novel Therapeutic Target?1. CD45 Overview CD45 (also known as PTPRC, Leukocyte Common Antigen) is a highly conserved transmembrane glycoprotein tyrosine phosphatase, widely expressed on the surface of all nucleated hematopoietic...
Detailed information

FLT1 (VEGFR-1): A Bidirectional Regulator of Angiogenesis and an Emerging Therapeutic TargetThe vascular endothelial growth factor receptor (VEGFR) family has long been a focus of therapeutic interest. Among them, FLT1 (VEGFR-1) stands out for its unique role as a "bidirectional regulator." FLT1 is far more tha...
Detailed information

Nicotinic Acetylcholine Receptor α1 Subunit (CHRNA1): Structure, Functional Mechanisms, and Disease-Related Research Progress1. Background of CHRNA1 1.1 Molecular Structure and Functional Characteristics The CHRNA1 gene is located on human chromosome 2q31.1 and encodes the α1 subunit of the nicotinic acetylchol...
Detailed information

PTPRD: The Overlooked Signaling Hub from Neurodevelopment to Cancer SuppressionProtein tyrosine phosphatase receptor type D (PTPRD) is a key member of the protein tyrosine phosphatase (PTP) family, belonging to the transmembrane receptor-type phosphatases. It precisely regulates diverse intracellul...
Detailed information